Trinity Biotech plc (TRIB) shares jumped 8.40% in after-hours on Friday, January 07, 2021, and closed the daily trading at $1.42. However, in the regular trading session, TRIB’s stock lost 5.07% to close. The stock volume remained 0.12 million shares. TRIB shares have fallen 67.17% over the last 12 months, and they have moved down 8.39% in the past week. Over the past three months, the stock has lost 41.52%, while over the past six months, it has slid down 44.26%. The company has a current market of $28.79 million and its outstanding shares stood at 20.90 million.
Let’s have a look at its recent news.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
>> 7 Top Picks for the Post-Pandemic Economy <<
TRIB latest financial news
On December 15, 2021, Trinity Biotech plc (TRIB) announced results for the quarter that ended September 30, 2021.
Read More
- Underdog Growth Stocks You Should Keep an Eye on in 2021
- Are You Looking for Dividend Paying Stocks? Here are the Best Buys in 2021
Q3 2021 financial highlights
- TRIB reported total revenue of $22.0 million in Q3 2021 compared to $32.0 million in Q3 2020.
- The total cost of revenue was $13.1 million in Q3 2021 compared to $15.3 million in Q3 2020.
- In Q3 2021, the gross profit was $8.9 million compared to $16.7 million in Q3 2020.
- Selling, general and administrative expenses were $5.88 million compared to $6.3 million in Q3 2020.
- It earned a net income of $1.32 million in Q3 2021 compared to $7.3 million net income in the comparable period of 2020.
- The company ended the third quarter with cash and cash equivalents of $27.5 million.
TRIB term loan facility
Trinity Biotech plc (TRIB) and its subsidiaries entered into $81,250,000 senior secured term loan credit facility with Perceptive Advisors, an investment manager with expertise in healthcare. Proceeds from the Term Loan, along with existing cash and the issuance of new American Depositary Shares in the Company, will be used to retire the Notes.
TRIB exchange agreement
The Company also entered into exchange agreements with five institutional investors that hold approximately $99,700,000 of the outstanding Notes, which are puttable by the holders to the Company, at par, in April 2022.
Under the terms of this agreement, each holder will receive $0.87 of cash and the equivalent of $0.08 of the Company’s ADS.
>> 7 Top Picks for the Post-Pandemic Economy <<
Conclusion
We have no recent news even any news for January 2022 so we are not sure why its stock went up in the after-hours trading on Friday. Let’s see how it performs on Monday?
